TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07469891: A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Sponsor: Prelude Therapeutics Incorporated · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$2,073,456

Rescue Site Savings

+$1,382,304

Unlock Full NCT07469891 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07469891 Rescue Dossier →